Evidence & regulatory context
- Mechanism
- No confident ChEMBL entity (recombinant protein domain acting as an HMGB1 antagonist). CTgov search for 'HMGB1 A box' returned only observational biomarker studies measuring circulating HMGB1 (NCT02206412, NCT02490644), not administration of the A box protein; n_trials=0, flagged for manual review.
- Target
- Not recorded
- Injury models
- Other
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseOtherICRMalen = 60After pancreatitis induction
Model: L-arginine-induced acute pancreatitis with lung injury
HMGB1 A box lowered lung HMGB1 and MPO and reduced lung histological injury in mice with acute pancreatitis.
Extraction: extract · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.